AnalystsMichael Ulz
Michael Ulz's Stock Forecasts

Analyst Ranking
Top 17%
#939 out of 5515 analysts
Average Return
+9.65%
Win Rate
41%42 out of 102
Risk vs Reward
Poor
Good

Michael Ulz's 5 best and worst ratings

Name / TickerGain/LossEntry PriceExit PricePeriodRating
Kyverna Therapeutics IncKYTX
+335.86%$1.98$8.63
2025-04-01 -
2026-03-31
Strong Buy
Silence Therapeutics PLCSLN
+310.96%$5.29$21.74
2023-07-24 -
2024-07-23
Strong Buy
Alpine Immune Sciences IncALPN
+300.75%$16.07$64.40
2023-11-03 -
2024-04-11
Strong Buy
Silence Therapeutics PLCSLN
+261.98%$5.76$20.85
2023-06-12 -
2024-06-11
Strong Buy
Iveric Bio IncISEE
+255.14%$11.19$39.74
2022-07-07 -
2023-07-06
Strong Buy

Michael Ulz Analyst Color

Get additional color on Michael Ulz's coverage of popular stocks

Michael Ulz's Stock Coverage

Name / TickerNo. RatingsRatingPrice TargetUpside/DownsideActionDate
Dyne Therapeutics IncDYN
6Strong Buy$36.00+110.40%Maintains
11 days ago
Ionis Pharmaceuticals IncIONS
11Strong Buy$104.00+134.02%Maintains
12 days ago
Silence Therapeutics PLCSLN
13Strong Buy$32.00+162.30%Maintains
a month ago
Alnylam Pharmaceuticals IncALNY
15Hold$300.00+25.23%Maintains
2 months ago
Arrowhead Pharmaceuticals IncARWR
9Strong Buy$120.00+80.51%Maintains
2 months ago
Mirum Pharmaceuticals IncMIRM
8Strong Buy$150.00+63.35%Maintains
3 months ago
Aardvark Therapeutics IncAARD
3Strong Sell$3.00-44.24%Downgrades
4 months ago
Karyopharm Therapeutics IncKPTI
9Buy$15.00+697.87%Maintains
6 months ago
Cabaletta Bio IncCABA
7Strong Buy$13.00+409.80%Maintains
6 months ago
Fractyl Health IncGUTS
3Hold$2.00+233.33%Downgrades
8 months ago
Kyverna Therapeutics IncKYTX
3Strong Buy$25.00+250.63%Maintains
10 months ago
Viking Therapeutics IncVKTX
4Strong Buy$102.00+251.85%Maintains
a year ago
Y Mabs Therapeutics IncYMAB
7Strong Sell$7.00N/AMaintains
2 years ago
Iovance Biotherapeutics IncIOVA
4Buy$20.00N/AMaintains
2 years ago
Third Harmonic Bio IncTHRD
5Hold$5.00N/ADowngrades
2 years ago
Akero Therapeutics IncAKRO
4Strong Buy$96.00N/AMaintains
2 years ago
Blueprint Medicines CorpBPMC
9Hold$115.00N/AMaintains
2 years ago
Alpine Immune Sciences IncALPN
4Hold$65.00N/ADowngrades
2 years ago
Fate Therapeutics IncFATE
7Hold$7.00N/AMaintains
3 years ago
Kalaris Therapeutics IncKLRS
4Strong Sell$11.50N/ADowngrades
3 years ago
Oric Pharmaceuticals IncORIC
2Buy$27.00N/AMaintains
3 years ago
Mirati Therapeutics IncMRTX
8Hold$37.00N/AMaintains
3 years ago
Iveric Bio IncISEE
3Strong Buy$35.00N/AMaintains
3 years ago
Senti Biosciences Holdings IncSNTI
3Hold$20.00N/AMaintains
3 years ago
Rocket Pharmaceuticals IncRCKT
1Strong Buy$45.00N/AInitiates Coverage On
4 years ago
Xilio Therapeutics IncXLO
3Strong Buy$140.00N/AMaintains
4 years ago
Allakos IncALLK
4Hold$8.00N/AMaintains
4 years ago
Taysha Gene Therapies IncTSHA
1Hold$3.00N/ADowngrades
4 years ago
Vir Biotechnology IncVIR
1Hold$30.00N/AUpgrades
4 years ago
Horizon Therapeutics Public Ltd CoHZNP
2Strong Buy$90.00N/AMaintains
4 years ago
Jounce Therapeutics IncJNCE
3Hold$7.00N/ADowngrades
4 years ago
Freeline Therapeutics Holdings PLCFRLN
1HoldN/AN/ADowngrades
5 years ago
Tectonic Therapeutic IncTECX
2Hold$36.00N/AMaintains
5 years ago
Igm Biosciences IncIGMS
2Hold$38.00N/ADowngrades
5 years ago
Iteos Therapeutics IncITOS
1Buy$45.00N/AInitiates Coverage On
6 years ago
Neurogene IncNGNE
1Buy$125.00N/AInitiates Coverage On
6 years ago
Mersana Therapeutics IncMRSN
2Buy$500.00N/AMaintains
6 years ago
Atreca IncBCEL
1Buy$30.00N/AInitiates Coverage On
6 years ago
Merrimack Pharmaceuticals IncMACK
2Hold$4.00N/AMaintains
8 years ago
Aceragen IncACGN
1Buy$4.00N/AMaintains
8 years ago
Ultragenyx Pharmaceutical IncRARE
1Buy$80.00N/AMaintains
9 years ago
Amicus Therapeutics IncFOLD
2Buy$15.00N/AMaintains
9 years ago
Tesaro IncTSRO
1Hold$182.00N/ADowngrades
10 years ago
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.